117 related articles for article (PubMed ID: 21378351)
21. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
[TBL] [Abstract][Full Text] [Related]
22. New developments in chemotherapy for advanced non-small cell lung cancer.
Raez LE; Lilenbaum R
Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
[TBL] [Abstract][Full Text] [Related]
23. [Maintenance treatment of non-small cell lung cancer].
Hansen O; Schytte T
Ugeskr Laeger; 2010 Mar; 172(12):954. PubMed ID: 20334788
[No Abstract] [Full Text] [Related]
24. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
de Marinis F; Grossi F
Oncologist; 2008; 13 Suppl 1():14-20. PubMed ID: 18263770
[TBL] [Abstract][Full Text] [Related]
25. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Manson GV; Ma PC
Clin Lung Cancer; 2010 Jan; 11(1):57-60. PubMed ID: 20085869
[TBL] [Abstract][Full Text] [Related]
26. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Langer CJ; Mok T; Postmus PE
Cancer Treat Rev; 2013 May; 39(3):252-60. PubMed ID: 22703830
[TBL] [Abstract][Full Text] [Related]
27. Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question.
Galetta D; Rossi A; Pisconti S; Millaku A; Colucci G
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S30-3. PubMed ID: 21129607
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
[TBL] [Abstract][Full Text] [Related]
29. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W
J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122
[TBL] [Abstract][Full Text] [Related]
30. Overview of MTA in the treatment of non-small cell lung cancer.
Postmus PE; Green MR
Semin Oncol; 1999 Feb; 26(1 Suppl 4):31-6. PubMed ID: 10201519
[TBL] [Abstract][Full Text] [Related]
31. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
Bearz A; Garassino I; Cavina R; Favaretto A; Boccalon M; Talamini R; Berretta M; Spazzapan S; Simonelli C; Santoro A; Tirelli U
Lung Cancer; 2008 May; 60(2):240-5. PubMed ID: 18022729
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
[TBL] [Abstract][Full Text] [Related]
33. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
35. Second-line treatment options in advanced non-small cell lung cancer: current status.
Cullen M
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S3-8. PubMed ID: 16472703
[TBL] [Abstract][Full Text] [Related]
36. Pemetrexed in advanced non-small-cell lung cancer.
Fuld AD; Dragnev KH; Rigas JR
Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
[TBL] [Abstract][Full Text] [Related]
37. Use of novel second-line targeted therapies in non-small cell lung cancer.
Massarelli E; Herbst RS
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
[TBL] [Abstract][Full Text] [Related]
39. Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent?
Paesmans M; Berghmans T; Sculier JP
Lung Cancer; 2007 Feb; 55(2):135-6. PubMed ID: 17118490
[No Abstract] [Full Text] [Related]
40. Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827.
Bartminski W
Rev Port Pneumol; 2009; 15(3):555-9; author reply 560-6. PubMed ID: 19526635
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
